Last, ATF2, the associated mRNA of ATF2 lncRNA, has been implicated in the progression and therapeutic resistance of many solid cancers, including melanoma [71], breast cancer [72], hepatocellular carcinoma [73], lung cancer [74], and prostate cancer [75]. The gene discussed is ATF2; the disease is prostate carcinoma.